Next Article in Journal
Anti-Inflammatory Effect of Atorvastatin and Rosuvastatin on Monosodium Urate-Induced Inflammation through IL-37/Smad3-Complex Activation in an In Vitro Study Using THP-1 Macrophages
Next Article in Special Issue
Pharmacogenomics: A Genetic Approach to Drug Development and Therapy
Previous Article in Journal
Evaluating the Physicochemical Properties–Activity Relationship and Discovering New 1,2-Dihydropyridine Derivatives as Promising Inhibitors for PIM1-Kinase: Evidence from Principal Component Analysis, Molecular Docking, and Molecular Dynamics Studies
Previous Article in Special Issue
Genetic Variations and Antibiotic-Related Adverse Events
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt

by
Fadya M. Elgarhy
1,2,†,
Abdallah Borham
1,†,
Noha Alziny
1,
Khlood R. AbdElaal
3,
Mahmoud Shuaib
1,
Abobaker Salem Musaibah
1,
Mohamed Ali Hussein
1 and
Anwar Abdelnaser
1,*
1
Institute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt
2
Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo 4435121, Egypt
3
Graduate Program of Biotechnology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2024, 17(7), 881; https://doi.org/10.3390/ph17070881
Submission received: 23 April 2024 / Revised: 19 June 2024 / Accepted: 29 June 2024 / Published: 3 July 2024
(This article belongs to the Special Issue Pharmacogenomics - A Genetic Approach to Drug Therapy and Development)

Abstract

Pharmacogenomics (PGx) is the hope for the full optimization of drug therapy while minimizing the accompanying adverse drug events that cost billions of dollars annually. Since years before the century, it has been known that inter-individual variations contribute to differences in specific drug responses. It is the bridge to what is well-known today as “personalized medicine”. Addressing the drug’s pharmacokinetics and pharmacodynamics is one of the features of this science, owing to patient characteristics that vary on so many occasions. Mainly in the liver parenchymal cells, intricate interactions between the drug molecules and enzymes family of so-called “Cytochrome P450” occur which hugely affects how the body will react to the drug in terms of metabolism, efficacy, and safety. Single nucleotide polymorphisms, once validated for a transparent and credible clinical utility, can be used to guide and ensure the succession of the pharmacotherapy plan. Novel tools of pharmacoeconomics science are utilized extensively to assess cost-effective pharmacogenes preceding the translation to the bedside. Drug development and discovery incorporate a drug-gene perspective and save more resources. Regulations and laws shaping the clinical PGx practice can be misconceived; however, these pre-/post approval processes ensure the product’s safety and efficacy. National and international regulatory agencies seek guidance on maintaining conduct in PGx practice. In this patient-centric era, social and legal considerations manifest in a way that makes them unavoidable, involving patients and other stakeholders in a deliberate journey toward utmost patient well-being. In this comprehensive review, we contemporarily addressed the scientific leaps in PGx, along with various challenges that face the proper implementation of personalized medicine in Egypt. These informative insights were drawn to serve what the Egyptian population, in particular, would benefit from in terms of knowledge and know-how while maintaining the latest global trends. Moreover, this review is the first to discuss various modalities and challenges faced in Egypt regarding PGx, which we believe could be used as a pilot piece of literature for future studies locally, regionally, and internationally.
Keywords: PGx; pharmacogenomics; regulatory; drug approval; personalized medicine PGx; pharmacogenomics; regulatory; drug approval; personalized medicine

Share and Cite

MDPI and ACS Style

Elgarhy, F.M.; Borham, A.; Alziny, N.; AbdElaal, K.R.; Shuaib, M.; Musaibah, A.S.; Hussein, M.A.; Abdelnaser, A. From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt. Pharmaceuticals 2024, 17, 881. https://doi.org/10.3390/ph17070881

AMA Style

Elgarhy FM, Borham A, Alziny N, AbdElaal KR, Shuaib M, Musaibah AS, Hussein MA, Abdelnaser A. From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt. Pharmaceuticals. 2024; 17(7):881. https://doi.org/10.3390/ph17070881

Chicago/Turabian Style

Elgarhy, Fadya M., Abdallah Borham, Noha Alziny, Khlood R. AbdElaal, Mahmoud Shuaib, Abobaker Salem Musaibah, Mohamed Ali Hussein, and Anwar Abdelnaser. 2024. "From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt" Pharmaceuticals 17, no. 7: 881. https://doi.org/10.3390/ph17070881

APA Style

Elgarhy, F. M., Borham, A., Alziny, N., AbdElaal, K. R., Shuaib, M., Musaibah, A. S., Hussein, M. A., & Abdelnaser, A. (2024). From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt. Pharmaceuticals, 17(7), 881. https://doi.org/10.3390/ph17070881

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop